$OMER
OMEROS CORP

2022 Q4 Form 10-Q Financial Statement

#000155837022017153 Filed on November 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.59M $12.20M
YoY Change -75.22% -41.53%
% of Gross Profit
Research & Development $26.55M $38.57M
YoY Change -77.65% 42.51%
% of Gross Profit
Depreciation & Amortization $163.0K $320.0K
YoY Change -49.69% 0.95%
% of Gross Profit
Operating Expenses $40.14M $38.57M
YoY Change -76.88% 42.51%
Operating Profit -$50.77M
YoY Change 177.41%
Interest Expense -$7.903M $4.932M
YoY Change -59.82% 0.43%
% of Operating Profit
Other Income/Expense, Net $1.993M $906.0K
YoY Change 14.54% 96.53%
Pretax Income -$46.05M -$54.79M
YoY Change -75.96% 141.34%
Income Tax $0.00
% Of Pretax Income
Net Earnings $128.7M -$17.46M
YoY Change -33.72% -23.11%
Net Earnings / Revenue
Basic Earnings Per Share -$0.28
Diluted Earnings Per Share $2.05 -$0.28
COMMON SHARES
Basic Shares Outstanding 62.73M 62.73M
Diluted Shares Outstanding 62.73M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $194.9M $221.0M
YoY Change 23.94% 338.66%
Cash & Equivalents $11.00M $145.5M
Short-Term Investments $183.9M $75.43M
Other Short-Term Assets $6.300M $5.983M
YoY Change -23.32% -6.03%
Inventory
Prepaid Expenses
Receivables $241.8M $60.86M
Other Receivables $255.0K $741.0K
Total Short-Term Assets $443.2M $288.5M
YoY Change 78.76% 215.87%
LONG-TERM ASSETS
Property, Plant & Equipment $23.25M $24.31M
YoY Change -22.5% -21.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.054M $1.054M
YoY Change 0.0% -12.96%
Total Long-Term Assets $147.7M $169.0M
YoY Change -13.76% 426.81%
TOTAL ASSETS
Total Short-Term Assets $443.2M $288.5M
Total Long-Term Assets $147.7M $169.0M
Total Assets $591.0M $457.6M
YoY Change 40.95% 270.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.989M $17.09M
YoY Change -55.31% 70.45%
Accrued Expenses $30.55M $18.02M
YoY Change -7.8% -34.96%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $95.96M
YoY Change
Total Short-Term Liabilities $136.4M $39.51M
YoY Change 163.34% -7.72%
LONG-TERM LIABILITIES
Long-Term Debt $346.5M $439.8M
YoY Change 10.54% 40.51%
Other Long-Term Liabilities $22.42M $24.53M
YoY Change -25.88% -19.01%
Total Long-Term Liabilities $368.9M $464.4M
YoY Change 7.33% 35.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $136.4M $39.51M
Total Long-Term Liabilities $368.9M $464.4M
Total Liabilities $505.3M $503.9M
YoY Change 27.76% 30.49%
SHAREHOLDERS EQUITY
Retained Earnings -$635.7M -$764.5M
YoY Change -6.94% -20.68%
Common Stock $721.4M $718.1M
YoY Change 2.05% 2.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $85.68M -$46.31M
YoY Change
Total Liabilities & Shareholders Equity $591.0M $457.6M
YoY Change 40.95% 270.7%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income $128.7M -$17.46M
YoY Change -33.72% -23.11%
Depreciation, Depletion And Amortization $163.0K $320.0K
YoY Change -49.69% 0.95%
Cash From Operating Activities -$25.38M -$26.44M
YoY Change 39.35% 11.74%
INVESTING ACTIVITIES
Capital Expenditures $13.00K $3.000K
YoY Change -117.57% -102.91%
Acquisitions
YoY Change
Other Investing Activities -$108.5M $33.00M
YoY Change -196.43% 83.32%
Cash From Investing Activities -$108.5M $33.00M
YoY Change -196.51% 84.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -651.0K 124.8M
YoY Change -19.63% 26016.53%
NET CHANGE
Cash From Operating Activities -25.38M -26.44M
Cash From Investing Activities -108.5M 33.00M
Cash From Financing Activities -651.0K 124.8M
Net Change In Cash -134.5M 131.4M
YoY Change -244.04% -2585.28%
FREE CASH FLOW
Cash From Operating Activities -$25.38M -$26.44M
Capital Expenditures $13.00K $3.000K
Free Cash Flow -$25.40M -$26.44M
YoY Change 39.99% 12.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.59
CY2021Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.34
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.87
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.93
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62730015
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62510727
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62728276
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62267557
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001285819
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.70
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62628855
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62730015
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.87
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.17
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.32
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.39
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34475
dei Entity Registrant Name
EntityRegistrantName
OMEROS CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1663741
dei Entity Address Address Line1
EntityAddressAddressLine1
201 Elliott Avenue West
dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98119
dei City Area Code
CityAreaCode
206
dei Local Phone Number
LocalPhoneNumber
676-5000
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
OMER
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
62730015
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
145533000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100808000
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
75431000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
56458000
CY2022Q3 omer Contract Royalty Asset Current
ContractRoyaltyAssetCurrent
47744000
CY2021Q4 omer Contract Royalty Asset Current
ContractRoyaltyAssetCurrent
44319000
CY2022Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
13854000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
38155000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5983000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8216000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
288545000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
247956000
CY2022Q3 omer Contract Royalty Asset Noncurrent
ContractRoyaltyAssetNoncurrent
143641000
CY2021Q4 omer Contract Royalty Asset Noncurrent
ContractRoyaltyAssetNoncurrent
140251000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22464000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28276000
CY2022Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1847000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1731000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1054000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1054000
CY2022Q3 us-gaap Assets
Assets
457551000
CY2021Q4 us-gaap Assets
Assets
419268000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
17089000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13400000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18016000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33134000
CY2022Q3 omer Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
4409000
CY2021Q4 omer Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
5255000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
39514000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
51789000
CY2022Q3 us-gaap Senior Long Term Notes
SeniorLongTermNotes
314819000
CY2021Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
313458000
CY2022Q3 omer Royalty Liabilities Non Current
RoyaltyLiabilitiesNonCurrent
125000000
CY2022Q3 omer Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
23533000
CY2021Q4 omer Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
29126000
CY2022Q3 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
999000
CY2021Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
1115000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62730015
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62628855
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
627000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
626000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
717509000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
706288000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-764450000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-683134000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-46314000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
23780000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
457551000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
419268000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38568000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25818000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86172000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
88448000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12198000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14010000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37079000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
42280000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
50766000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
39828000
us-gaap Costs And Expenses
CostsAndExpenses
123251000
us-gaap Costs And Expenses
CostsAndExpenses
130728000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-50766000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-39828000
us-gaap Operating Income Loss
OperatingIncomeLoss
-123251000
us-gaap Operating Income Loss
OperatingIncomeLoss
-130728000
CY2022Q3 us-gaap Interest Expense
InterestExpense
4932000
CY2021Q3 us-gaap Interest Expense
InterestExpense
4911000
us-gaap Interest Expense
InterestExpense
14799000
us-gaap Interest Expense
InterestExpense
14718000
CY2022Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
906000
CY2021Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
461000
us-gaap Interest And Other Income
InterestAndOtherIncome
2069000
us-gaap Interest And Other Income
InterestAndOtherIncome
1212000
CY2022Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-54792000
CY2021Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-44278000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-135981000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-144234000
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
37336000
CY2021Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
21575000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
54665000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
57848000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-17456000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22703000
us-gaap Net Income Loss
NetIncomeLoss
-81316000
us-gaap Net Income Loss
NetIncomeLoss
-86386000
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.87
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.70
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.17
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.32
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.59
CY2021Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.34
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.87
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.93
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.39
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62730015
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62510727
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62728276
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62267557
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-120752000
CY2021Q1 omer Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
6333000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
241000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3271000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-35090000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-221955000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1135000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3117000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-28593000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
806000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-246296000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
608000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
5694000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22703000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-262697000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
44725000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
23780000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
414000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3892000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-33011000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-4925000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3072000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-30849000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-32702000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3844000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-17456000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-46314000
us-gaap Profit Loss
ProfitLoss
-81316000
us-gaap Profit Loss
ProfitLoss
-86386000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
454000
us-gaap Share Based Compensation
ShareBasedCompensation
10808000
us-gaap Share Based Compensation
ShareBasedCompensation
12082000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1361000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1256000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
789000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1062000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-24301000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
30057000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1769000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5740000
omer Increase Decrease In Contract Royalty Asset Current
IncreaseDecreaseInContractRoyaltyAssetCurrent
6815000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-11544000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4796000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-61101000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-91507000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
103573000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
84600000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
81500000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
100000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
203000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19073000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
81292000
omer Proceeds From Liability For Future Royalties Received
ProceedsFromLiabilityForFutureRoyaltiesReceived
125000000
omer Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
414000
omer Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
8076000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
515000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
706000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
241000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
124899000
CY2021Q3 omer Share Based Payment Arrangement Expense Discontinuing Operations
ShareBasedPaymentArrangementExpenseDiscontinuingOperations
344000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3086000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7129000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100808000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10501000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
145533000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7415000
us-gaap Interest Paid Net
InterestPaidNet
13437000
us-gaap Interest Paid Net
InterestPaidNet
14889000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
139000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Omeros Corporation (“Omeros,” the “Company” or “we”) is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic diseases, including complement-mediated diseases and cancers related to dysfunction of the immune system, as well as addictive and compulsive disorders. We marketed our first drug product, OMIDRIA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (phenylephrine and ketorolac intraocular solution) 1% / 0.3% for use during cataract surgery or intraocular lens replacement in the United States (the “U.S.”) until we sold OMIDRIA and related business assets on December 23, 2021 (see “Sale of OMIDRIA Assets” below for additional information). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#fefefe;margin:0pt;">Our drug candidate narsoplimab, targeting mannan-binding lectin-associated serine protease-2 (“MASP-2”) and the lectin pathway of complement, is the subject of a biologics license application (“BLA”) pending before the U.S. Food and Drug Administration (“FDA”) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (“HSCT-TMA”). On October 18, 2021, we announced the receipt of a Complete Response Letter (“CRL”) from FDA indicating that the BLA could not be approved as submitted. In November 2022, we received the decision by FDA’s Office of New Drugs (“OND”) denying our appeal of the CRL. Although our appeal was denied, the decision proposes a path forward for resubmission of the BLA based on survival data from the completed pivotal trial versus a historical control group, with or without an independent literature analysis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#fefefe;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Clinical development of narsoplimab also includes programs focused on complement-mediated disorders, including immunoglobulin A (“IgA”) nephropathy, atypical hemolytic uremic syndrome (“aHUS”) and COVID-19. Our pipeline of investigational agents also includes: our long-acting MASP-2 inhibitor OMS1029, which is currently in a Phase 1 clinical trial, and OMS906, our inhibitor of mannan-binding lectin-associated serine protease 3 (“MASP-3”) targeting the alternative pathway of complement, which has completed a Phase 1 clinical trial and is being advanced into clinical programs for paroxysmal nocturnal hemoglobinuria (“PNH”) and complement 3 (“C3”) glomerulopathy. </p>
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
221000000.0
CY2022Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
13900000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-17500000
CY2022Q3 omer Non Cash Benefit Related To Revaluation Of Royalty Asset
NonCashBenefitRelatedToRevaluationOfRoyaltyAsset
29000000.0
CY2022Q3 us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
4600000
us-gaap Profit Loss
ProfitLoss
-81300000
omer Non Cash Benefit Related To Revaluation Of Royalty Asset
NonCashBenefitRelatedToRevaluationOfRoyaltyAsset
30500000
us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
12500000
CY2022Q3 omer Maximum Aggregate Offering Price
MaximumAggregateOfferingPrice
150000000.0
CY2022Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
5211000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12082000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include OMIDRIA contract royalty asset valuation, stock-based compensation expense, and accruals for clinical trials and manufacturing of drug product. We base our estimates on historical experience and on various other factors, including the impact of the COVID-19 pandemic, that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</p>
CY2022Q3 omer Royalty Liabilities Non Current
RoyaltyLiabilitiesNonCurrent
125000000.0
CY2022Q3 omer Disposal Group Including Discontinued Operation Contract Royalty Asset
DisposalGroupIncludingDiscontinuedOperationContractRoyaltyAsset
191385000
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
314819000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
320030000
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5162498
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6723358
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5158947
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7446640
CY2022Q3 omer Contract Royalty Asset Current
ContractRoyaltyAssetCurrent
47744000
CY2021Q4 omer Contract Royalty Asset Current
ContractRoyaltyAssetCurrent
44319000
CY2022Q3 omer Contract Royalty Asset Noncurrent
ContractRoyaltyAssetNoncurrent
143641000
CY2021Q4 omer Contract Royalty Asset Noncurrent
ContractRoyaltyAssetNoncurrent
140251000
CY2022Q3 omer Contract Royalty Asset
ContractRoyaltyAsset
191385000
CY2021Q4 omer Contract Royalty Asset
ContractRoyaltyAsset
184570000
CY2022Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
13113000
CY2021Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
36505000
CY2022Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
741000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1650000
CY2022Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
13854000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
38155000
CY2021Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
2000000.0
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
6572000
CY2022Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
11607000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
10764000
CY2022Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
9760000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
9033000
CY2022Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1847000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1731000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1100000
CY2022Q3 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
4958000
CY2021Q4 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
2430000
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
3703000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
5172000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3704000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3706000
CY2022Q3 omer Accrued Contract Research Costs
AccruedContractResearchCosts
2639000
CY2021Q4 omer Accrued Contract Research Costs
AccruedContractResearchCosts
3916000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2338000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
7455000
CY2021Q4 omer Accrued Sales Rebates Fees And Discounts Current
AccruedSalesRebatesFeesAndDiscountsCurrent
8442000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
674000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2013000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18016000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33134000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
145500000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100800000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2021 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
320030000
omer Share Based Payment Arrangement Expense Discontinuing Operations
ShareBasedPaymentArrangementExpenseDiscontinuingOperations
-139000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
313458000
CY2022Q3 omer Number Of Options To Extend Lease Term
NumberOfOptionsToExtendLeaseTerm
2
CY2022Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2022Q1 omer Decrease In Right Of Use Asset Due To Early Operating Lease Termination
DecreaseInRightOfUseAssetDueToEarlyOperatingLeaseTermination
4700000
CY2022Q1 omer Decrease In Lease Liability Due To Early Operating Lease Termination
DecreaseInLeaseLiabilityDueToEarlyOperatingLeaseTermination
5200000
CY2022Q1 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
500000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1659000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1961000
us-gaap Operating Lease Cost
OperatingLeaseCost
4529000
us-gaap Operating Lease Cost
OperatingLeaseCost
5528000
CY2022Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
250000
CY2021Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
243000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
570000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
854000
CY2022Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
32000
CY2021Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
40000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
123000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
127000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
813000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
863000
us-gaap Variable Lease Cost
VariableLeaseCost
2395000
us-gaap Variable Lease Cost
VariableLeaseCost
2667000
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
432000
CY2021Q3 us-gaap Sublease Income
SubleaseIncome
447000
us-gaap Sublease Income
SubleaseIncome
1377000
us-gaap Sublease Income
SubleaseIncome
1288000
CY2022Q3 us-gaap Lease Cost
LeaseCost
2322000
CY2021Q3 us-gaap Lease Cost
LeaseCost
2660000
us-gaap Lease Cost
LeaseCost
6240000
us-gaap Lease Cost
LeaseCost
7888000
omer Share Based Payment Arrangement Expense Continuing Operations
ShareBasedPaymentArrangementExpenseContinuingOperations
10947000
omer Share Based Payment Arrangement Expense Continuing Operations
ShareBasedPaymentArrangementExpenseContinuingOperations
11322000
omer Share Based Payment Arrangement Expense Discontinuing Operations
ShareBasedPaymentArrangementExpenseDiscontinuingOperations
760000
CY2022Q3 omer Share Based Payment Arrangement Expense Discontinuing Operations
ShareBasedPaymentArrangementExpenseDiscontinuingOperations
-28000
us-gaap Operating Lease Payments
OperatingLeasePayments
5312000
us-gaap Operating Lease Payments
OperatingLeasePayments
5521000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
598000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
684000
CY2022Q3 omer Long Term Purchase Commitment Termination Fee
LongTermPurchaseCommitmentTerminationFee
20600000
CY2021Q1 omer Cashless Exercise Of Warrants
CashlessExerciseOfWarrants
43115
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
200000
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
23.00
CY2022Q3 omer Share Based Payment Arrangement Expense Continuing Operations
ShareBasedPaymentArrangementExpenseContinuingOperations
3872000
CY2021Q3 omer Share Based Payment Arrangement Expense Continuing Operations
ShareBasedPaymentArrangementExpenseContinuingOperations
5350000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3844000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5694000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10808000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12709887
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.61
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2631334
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.96
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
101160
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
574203
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
13.58
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14665858
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.08
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y8M12D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
78000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
14202672
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.16
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y7M6D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
70000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
10277595
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.11
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y2M12D

Files In Submission

Name View Source Status
0001558370-22-017153-index-headers.html Edgar Link pending
0001558370-22-017153-index.html Edgar Link pending
0001558370-22-017153.txt Edgar Link pending
0001558370-22-017153-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
omer-20220930.xsd Edgar Link pending
omer-20220930x10q.htm Edgar Link pending
omer-20220930xex10d1.htm Edgar Link pending
omer-20220930xex31d1.htm Edgar Link pending
omer-20220930xex31d2.htm Edgar Link pending
omer-20220930xex32d1.htm Edgar Link pending
omer-20220930xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
omer-20220930_cal.xml Edgar Link unprocessable
omer-20220930_lab.xml Edgar Link unprocessable
omer-20220930_pre.xml Edgar Link unprocessable
omer-20220930x10q_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
omer-20220930_def.xml Edgar Link unprocessable